Imtiaz Samjoo
Senior Director, Value & Evidence
专长:
As Senior Director of the Value & Evidence team at EVERSANA, Imtiaz leads evidence synthesis projects that support global HEOR initiatives involving systematic literature reviews, indirect treatment comparisons, and health economic modeling, to support reimbursement and market
access for pharmaceuticals.
Imtiaz Samjoo is the Senior Director of Evidence Synthesis at EVERSANA. Imtiaz has more than 10 years of academic research and scientific writing experience, with expertise in molecular and clinical research and a specialty in anatomy, biochemistry, metabolism, and physiology. He has authored over 20 peer-reviewed scientific publications. His academic training includes an Honours BSc (Biology) from McMaster/Leeds University, an MSc in Physiology and Pharmacology (McMaster University) and a Ph.D. in Cell Biology and Metabolism (McMaster University).
At EVERSANA, Imtiaz specializes in the conduct and critical appraisal of evidence synthesis activities including traditional and network meta-analysis, advanced ITCs such as MAICs and STCs, ITC feasibility assessments, systematic and targeted literature reviews, developing objection handlers, gap and landscape assessments, product value communication tools, peer-reviewed manuscripts, value messages, slide decks, and conference abstracts and posters. Additionally, Imtiaz is involved in the development and implementation of tools that demonstrate the health economic value of pharmaceuticals and medical devices. These include cost-effectiveness, cost-consequence, and budget impact analysis models and sales force tools. He has worked in several therapeutic areas, including cardiovascular disease, diabetes, gastroenterology, mental illness, neurology, and oncology.
Articles by Imtiaz Samjoo
Enhancing Quality of Life in Advanced Breast Cancer: The Role of Palbociclib
Advanced breast cancer often comes with significant physical symptoms, such as pain and fatigue, as well as side effects from treatments. The diagnosis and treatment of advanced breast cancer can lead to anxiety, depression and stress. Improving a patient’s quality of life can help manage these symptoms more effectively, making daily life more bearable. Focusing […]
Filling in the Gaps: Predicting Treatment Effects From Surrogate Endpoints
Over the past 15 years, the treatment landscape for first-line metastatic castration-resistant prostate cancer (mCRPC) has undergone significant changes, marked by the approval and investigation of several new therapies. With multiple pharmacological treatments available for first-line mCRPC, network meta-analyses (NMAs) can serve as a valuable resource for evaluating clinical effectiveness that reflects current and local […]
A Review of Worldwide Indirect Treatment Comparison (ITC) Guidelines and Best Practices
Considering the challenges of conducting head-to-head clinical trials, indirect treatment comparisons (ITCs) offer valuable insights into clinical effectiveness that reflect current and local practices. These insights can help regulators and reimbursement agencies make better-informed decisions, thereby facilitating patient access to novel treatments. Recent methodological advancements in ITCs have led to the release of regional, national […]
Real-World Effectiveness of Treatments Post-CDK4/6i in Treating HR+/HER2- Locally Advanced or Metastatic Breast Cancer
Since the FDA’s approval of palbociclib plus letrozole in 2015, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), in combination with endocrine therapy (ET), have become the standard of care for treating hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced/metastatic breast cancer (HR+/HER2- LABC/mBC) in the first-line (1L) treatment setting. However, there is no clear standard […]
Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC
Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques, tumor genotyping has led to the identification of actionable driver alterations in NSCLC. The ROS1 gene encodes a tyrosine […]
Transforming Systematic Literature Reviews: Leveraging AI for Efficiency and Rigor
Systematic literature reviews (SLRs) are instrumental in supporting healthcare decision-making and market access. Traditionally, literature reviews require a resource-intensive process, thus highlighting the need for more efficient methodologies without compromising rigor or integrity. Over the past few years, artificial intelligence (AI) has emerged as a powerful tool that can significantly enhance efficiency in conducting reviews. […]
Uncovering Health Disparities: Exploring Social Determinants of Metastatic Prostate Cancer Survival
Author(s): Imtiaz A. Samjoo, MSc, PhD; Emily Rosta, MSc; Austin Lansing, MSc; Alexandra Hall, MPH Despite recent advancements in metastatic prostate cancer (mPC) treatment, prevention and care, progress has not equally manifested in all population groups. Though some recent reports suggest similar outcomes across races, there continue to be reports of racial disparity in disease […]
Eight Key Strategic Considerations When Launching a Global Indirect Treatment Comparison Program for New Products
Indirect treatment comparisons (ITCs) refer to a comparison of different healthcare interventions using data from separate studies, in contrast to a direct comparison within randomized controlled trials (RCTs). Indirect treatment comparisons are often used because of a lack of, or insufficient, evidence from head-to-head comparative trials. Indirect treatment comparisons have become valuable in evidence-based healthcare […]